Treace John T. - 10 Jun 2026 Form 4/A - Amendment Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: TMCI
Reported as of: 10 Jun 2026
Net transaction value: +$99,196
SEC form: 4/A - Amendment
Accepted by SEC: 12 Jun 2026, 09:26:46 UTC
Original report date: 11 Jun 2026
Prior SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Lisa Taylor as Attorney-in-fact for John Treace

Key filing fact

Treace John T. filed Form 4/A - Amendment for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 12 Jun 2026.

Key facts

This page summarizes Treace John T.'s Form 4/A - Amendment filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Jun 2026, 09:26.

Change

Previous filing in this sequence was filed on 01 Jun 2026.
Current net transaction value: +$99,196.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001856380 Primary reporting owner

Treace John T.

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: C/O TREACE MEDICAL CONCEPTS, INC., 100 PALMETTO PARK PLACE, PONTE VEDRA
Signature: /s/ Lisa Taylor as Attorney-in-fact for John Treace
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMCI transaction

Common Stock

Purchase

Transaction value: $59,213
Shares: +14,715
Change %: +0.2%
Price: $4.02
Shares after: 7,338,548
Date: 10 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

TMCI transaction

Common Stock

Purchase

Transaction value: $39,982
Shares: +9,891
Change %: +0.13%
Price: $4.04
Shares after: 7,348,439
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F3, F4, F5

TMCI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,605,000
Date: 10 Jun 2026
Ownership: By spouse
Footnotes: F6

TMCI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,471,250
Date: 10 Jun 2026
Ownership: By spouse as trustee of a trust
Footnotes: F6

TMCI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,839,063
Date: 10 Jun 2026
Ownership: As trustee of a trust
Footnotes: F7

TMCI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 408,816
Date: 10 Jun 2026
Ownership: As co-trustee of a trust
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

The original Form 4, filed on June 11, 2026, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a purchase that occurred on June 10, 2026 as a total of 29,430 shares purchased when in fact 14,715 shares of the Issuer's common stock were purchased.

Footnote F2

The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9300 to $4.1000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

Footnote F3

Includes 542,784 restricted stock units.

Footnote F4

The original Form 4, filed on June 11, 2026, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a purchase that occurred on June 11, 2026 as a total of 22,887 shares purchased when in fact 9,891 shares of the Issuer's common stock were purchased.

Footnote F5

The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9600 to $4.1700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

Footnote F6

The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.

Footnote F7

The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.